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Abstract 
The synthesis of a chemically cross-linked polymer hydrogel consisting exclusively of 
amino acids is described in this paper. A natural amino acid, aspartic acid was polymerized to 
polysuccinimide which was cross-linked by a tetrapeptide sequence designed for proteolytic 
degradation, and then the corresponding poly(aspartic acid) hydrogel was obtained by alkaline 
hydrolysis. The hydrogel dissolved in the presence of trypsin. According to in vitro cellular 
assays, the degradation products of the hydrogel cross-linked with the peptide were non-
cytotoxic and non-cytostatic. The sustained release of an encapsulated macromolecular model 
drug, FITC-dextran, was triggered by the degradation of the hydrogel induced by trypsin. These 
results suggest the potential application of the trypsin-responsive hydrogel for drug delivery in 
the small intestine.  
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1. Introduction 
Polymer hydrogels are applied as biosensing materials [1], scaffolds for tissue engineering 
[2] or as drug delivery vehicles [3] owing to their large water uptake, biocompatibility and 
responsive properties. A wide variety of polymers, cross-linkers and cross-linking methods are 
in our hand to design hydrogels with tailor-made properties like hydrogels responsive to pH, 
temperature, redox potential or other external stimuli [4–8]. Yet the most attractive stimulus for 
biomedical applications is the concentration gradient of biomolecules, like enzymes, in the 
human body. The most important advantages of using enzymes over other stimuli are their high 
selectivity, inherent biocompatibility and their availability at the site of action, i.e. they do not 
need to be added externally [9].  The possible responses to the presence of enzymes include 
swelling [10–13], gelation [14–18] or degradation. The degradation of polymer hydrogels can 
be classified into at least two different categories, such as the degradation of the polymer 
backbone [19,20] or that of the cross-linkers [16,21–39]. The third possibility, cleavage of 
pendant groups from the backbone chains may or may not result in the dissolution of the 
hydrogel [40]. Various enzymes have been reported to induce such a  response, e.g. dextranase 
[20], horseradish peroxidase [14,17,18] or various proteases [16,21–30,32–39]. The hydrogels 
responsive to enzymes can be used as scaffolds with controlled rate of degradation [16,21–
23,32,39] or in controlled drug delivery exploiting the change in the expression or activity of 
the enzymes at certain disease sites [27–29,35,36,41,42]. 
Hydrogels showing enzymatic response can be prepared by using peptide cross-linkers. The 
peptide sequence can be designed for selective cleavage by a protease enzyme available at the 
chosen therapeutic site. The presence of trypsin is a particularly attractive trigger for site-
specific drug delivery systems. Trypsin-degradable hydrogels have been already reported in the 
literature [26,29,42], and they can be utilised for the protection of bioactive molecules (e.g. 
therapeutic proteins) in the stomach and for the release of them in the small intestine. Van Dijk 
and co-workers [26] reported the synthesis of a hydrogel by the use of the Cu(I)-catalyzed 1,3-
dipolar cycloaddition of a trypsin-responsive bis-azido peptide and a star-shaped alkyne 
derivatized PEG. The degradation of the resulting hydrogel was induced by trypsin. Horava and 
co-workers [29] recently reported a pH- and enzyme-responsive microgel of 
poly(methacrylic acid)-g-poly(ethylene glycol) cross-linked with an oligopeptide composed of 
arginine (Arg, R), glycine (Gly, G) and lysine (Lys, K) for targeted cleavage by trypsin and 
resistance to degradation by pepsin. The hydrogel can be used for the oral administration of 
haematological factor IX for the treatment of haemophilia B. Enzymatically degradable 
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hydrogels are often synthesized by the copolymerization of acrylated peptide derivatives 
[21,32–37]. Various click reactions are also used such as the Michael addition of cysteine thiols 
with vinyl-sulfone [16,22,39], maleimide [23] or norbornene functionalised poly(ethylene 
glycol) [24,38]. Copper catalyzed Huisgen cycloaddition of azido-terminated PEG and alkyne-
terminated peptides [25] or alkynated PEG and peptide azides [26] can be used as well. The 
carboxyl groups of the polymer and the terminal amine groups of the peptides can be coupled 
by p-nitrophenyl ester activation [27] or carbodiimide chemistry [28–30,42]. The drawback of 
all these methods is that they require the derivatization of the polymer before the cross-linking 
reaction, and the acrylate polymers are not biodegradable.  
Apart from polymer hydrogels, enzyme-responsive physical gels have also been reported in 
the literature. Pochan and Schneider prepared a series of synthetic oligopeptides which are able 
to fold into β-hairpin, then self-assemble into a β-sheet rich network to form a self-supporting 
hydrogel [43]. The oligopeptides composed of 20 amino acids include a six residue sequence 
that is cleavable by matrix metalloproteinase-13, thus, these peptides have a potential as 
extracellular matrices for facilitating repair of damaged tissues [44]. 
In this work, a polymer hydrogel with trypsin-induced degradation was prepared exclusively 
from amino acids. The polymer backbone of the hydrogel is a pH-responsive poly(aspartic acid) 
(PASP) [5,6], a synthetic polymer, which is biocompatible [45] and biodegradable [46] due to 
its protein-like poly(amino acid) structure. PASP has a robust synthesis method allowing 
precise control over molecular structure [47,48]. The precursor anhydride of PASP, 
polysuccinimide (PSI), reacts with primary amines under mild reaction conditions. Thus, PSI 
can be cross-linked by any peptide bearing amine groups at both termini, which means that no 
activation of the peptide is required before cross-linking. In the present work, a tetrapeptide, 
composed of phenylalanine (Phe, F), arginine (Arg, R) and lysine (Lys, K), abbreviated as 
FRFK, was used as trypsin-degradable cross-linker. Degradation, biocompatibility, and drug 
release properties of the hydrogel were studied in comparison with a non-degradable 
poly(aspartic acid) hydrogel. 
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2. Experimental 
2.1. Materials 
Imidazole (99%), potassium chloride (KCl), sodium chloride (NaCl), dibasic sodium 
phosphate dihydrate (Na2HPO4·2H2O), mesitylene (99%), phosphoric acid (85% H3PO4), 
methanol, dibutylamine (DBA, 99%), and dithiothreitol (DTT, 99%) were purchased from 
Reanal (Hungary). Monobasic potassium phosphate (KH2PO4, 99.5%) L-aspartic acid (extra 
pure), sulpholane (99%), cystamine dihydrochloride (CA, 98%), and HPLC-grade acetonitrile 
(MeCN) were bought from Merck. Hydrochloric acid (HCl), dimethyl sulfoxide (DMSO), 
dichloromethane (DCM), dimethylformamide (DMF), and diethylether were purchased from 
Molar Chemicals (Hungary). Deuterated dimethyl sulfoxide (DMSO-d6, 99.9 atom% D, 
containing 0.03 v/v% tetramethylsilane), trypsin (from porcine pancreas, Type IX-S, 13000-
20000 BAEE units/mg protein), and FITC-dextran (Mw = 70 kDa; FITC:glucose = 1:250) were 
bought from Sigma-Aldrich. 
All amino acid derivatives (Fmoc-Phe-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH), 2-
chlorotrityl-chloride resin, coupling reagents (N,N′-diisopropylcarbodiimide (DIC), 1-
hydroxybenzotriazole (HOBt)) and scavenger (triisopropylsilan (TIS)) were purchased from 
IRIS Biotech GmbH (Germany). Piperidine and trifluoroacetic acid (TFA) were Fluka products.  
The imidazole buffer (pH = 8; I = 0.15 M) was prepared by dissolving 6.81 g imidazole and 
10.39 g KCl in 1 dm3 of water, the pH was adjusted with 1 M HCl. The phosphate buffered 
saline (PBS) solution of pH = 7.4 was prepared by dissolving 8.00 g of NaCl, 0.20 g of KCl, 
1.44 g of Na2HPO4·2H2O and 0.12 g of KH2PO4 in 1 dm3 of water, the pH being adjusted with 
0.1 M HCl. The pH of the buffer solutions was checked with a Radelkis OP-271/1 pH/ion 
analyser.  
For the in vitro cell culturing assays, RPMI-1640 medium, gentamicin, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and fetal calf serum were 
obtained from Sigma-Aldrich. The 96-well microtest plates were the products of Sarstedt 
(Hungary). 
All reagents were used without further purification and their quality was “for analysis” 
unless otherwise noted. Experiments were performed at room temperature (T = 25 °C) unless 
otherwise indicated. Ultrapure water (ρ > 18.2 MΩ·cm, Millipore) was used for the preparation 
of aqueous solutions. 
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2.2. The synthesis of polysuccinimide  
Polysuccinimide (PSI) was synthesized by the thermal polycondensation of aspartic acid in 
a mixture of mesitylene and sulpholane (7/3 weight ratio) at 160 °C with 85% H3PO4 as catalyst 
(the molar ratio of H3PO4 to aspartic acid was 16%). After 7 h, the resultant polymer was filtered 
and dissolved in DMF, then precipitated with excess amount of water. The precipitate was 
washed with water and MeOH and dried at 80 °C. The chemical structure of PSI was confirmed 
by 1H NMR (300 MHz, DMSO-d6, δ: 5.10 (d, 1H, CH); 3.20 and 2.75 (s,s, 2H, CH2)). PSI was 
hydrolysed to poly(aspartic acid) (PASP) in a mildly alkaline solution (imidazole buffer, 
pH = 8, 24 h), the solution was dialysed against water and the solid PASP was obtained by 
freeze-drying. The average molecular weight of the resultant PASP was determined by HPLC 
size-exclusion chromatography (SEC). A Nucleogel GFC-300 column was used (molecular 
weight range of 1-100 kDa) with PBS eluent. The average molecular weight of PASP was 
calculated to be Mw = 56.1 kDa with a polydispersity index (PDI) of 1.07. 
 
2.3. Synthesis of the peptide cross-linker 
TFA salt of FRFK was synthesized by solid phase methodology using Fmoc-chemistry on 
2-chlorotrityl-chloride resin [49] using diisopropylcarbodiimide/1-hydroxybenztriazole 
(DIC/HOBt) as coupling reagent. The protecting group of arginine and lysine were 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) and tert-butyloxycarbonyl (Boc) groups, 
respectively. The tetrapeptide was cleaved off the resin in a solution containing 95% TFA, 2.5% 
water and 2.5% triisopropylsilane by stirring the solution for 2 h. The resin was removed by 
filtration, the filtrate was dropped into cold ether to precipitate the peptide. The ether was 
distilled three times to remove free TFA. The crude products were purified by semi-preparative 
reversed-phase high-performance liquid chromatography (RP-HPLC) and the purified 
compounds were characterized by analytical RP-HPLC (Fig. S1) and electrospray ionization 
ion trap mass spectrometry (ESI-IT-MS). The molecular mass of the FRFK tetrapeptide was 
596.5 Da (Fig. S2). 
 
2.4. Synthesis of poly(aspartic acid) hydrogel cross-linked with the tetrapeptide 
The poly(aspartic acid) hydrogel cross-linked with the tetrapeptide (PASP-FRFK) was 
prepared by dissolving 14.6 mg (150 μmol) PSI and 20.6 mg (25 μmol) FRFK∙2TFA in 
106.7 mg DMSO, then 8.1 mg (62.5 µmol) dibutylamine (DBA) was added to initiate gelation, 
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and the solution was vortexed. The gelation was carried out overnight, then the gel was placed 
into imidazole buffer (pH = 8) to hydrolyse unreacted succinimide rings. The buffer was 
replaced daily for 3 days. PASP-FRFK was stored in PBS (pH = 7.4) for further experiments. 
PASP-FRFK gel loaded with the model drug was prepared by dissolving PSI and FRFK in 
DMSO along with 2.91 mg FITC-dextran (20 w/w% of the polymer) before the gelation. An 
oscillatory rheometer (Anton Paar Physica MCR 301, Austria) with plate-plate geometry (PP25, 
diameter 25 mm, measuring gap 2.75 mm, normal force 0.5 N) was used to assess the 
mechanical properties of the hydrogel. Frequency sweep measurements were performed in the 
range of linear viscoelasticity with a strain of 1% in the angular frequency range of 𝜔 = 1-100 
rad/s. The temperature was maintained at 25.0 ± 0.1 °C using a Peltier system included in the 
rheometer. Three parallel samples were measured. 
 
2.5. Synthesis of poly(aspartic acid) hydrogel cross-linked with cystamine 
The poly(aspartic acid) hydrogel cross-linked with cystamine (PASP-CA) was prepared by 
dissolving 14.6 mg PSI and 5.6 mg cystamine dihydrochloride in 123.3 mg DMSO, then 6.5 
mg (50 μmol) DBA was added, and the solution was vortexed. After gelation, the gel was 
hydrolysed in imidazole buffer (pH = 8). The buffer was replaced daily for 3 days, then PASP-
CA was stored in PBS (pH = 7.4) for further experiments. PASP-CA gel loaded with model 
drug was prepared similarly, but 2.91 mg FITC-dextran was also dissolved in DMSO along 
with PSI and cystamine dihydrochloride before the cross-linking reaction. 
 
2.6. Enzymatic degradation of the PASP-FRFK hydrogel  
A gravimetric method was used to study the degradation of the PASP-FRFK hydrogels. 
Hydrogel pieces swollen in PBS were weighed (initial mass: ~60 mg), then immersed in 5 ml 
trypsin solution prepared in PBS (c = 2 mg/ml). Hydrogels were weighed at predetermined time 
intervals. Relative mass was defined as the percentage ratio of the mass of the hydrogels at a 
given time to the initial mass. PASP-FRFK in PBS without trypsin and PASP-CA in PBS 
containing 2 mg/ml trypsin were used as reference samples. The samples were measured in 
triplicate. Experiments were carried out at 37 °C. Degradation was also followed by taking 
photographs of the gels under a UV lamp (Phillips TL-D 18W BLB) at 25 °C.  
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2.7. In vitro cytotoxicity and cytostatic activity  
Before the in vitro assays, PASP-FRFK hydrogel was digested by trypsin. The hydrogels 
(approximately 150 mg) were digested using 200 µl 2.5% trypsin solution for 4 h, 8 h, 24 h at 
37 °C and were shaken every hour. The digestion was stopped by 750 µl fetal bovine serum 
(FBS). As control samples, 2.5% trypsin solutions were incubated at 37 °C and were treated 
with FBS after 4 h, 8 h, 24 h. The supernatants of the samples were removed, freezed at –80 °C 
until the determination of their in vitro cytotoxicity and cytostatic activity.  
The in vitro cytotoxicity of PASP, FRFK and the degradation products of the digested PASP-
FRFK hydrogel were determined by MTT assay. Adherent HepG2 human hepatoma (ATCC: 
HB-8065, [50,51]) cells were cultured in RPMI-1640 medium supplemented with 10% fetal 
calf serum, 2 mM L-glutamine, and 160 μg/ml gentamicin. Cell cultures were kept at 37 °C in 
a humidified atmosphere with 5% CO2. The cells were grown to confluency and were placed 
into a 96-well plate with an initial cell number of 5.0 x 103 and initial volume of 100 μl per 
well. After 24 h incubation at 37 °C, cells were treated with a series of diluted solutions (100 μl 
each) of PASP, FRFK, or the supernatant of digested PASP-FRFK gel, the final volumes were 
200 μl. Cells were incubated for 16 h. Control cells were treated with serum free medium 
(RPMI-1640, in the case of PASP and FRFK) or with trypsin-FBS solution (in the case of 
digestion products) at 37 °C for 16 h. The cells were washed three times by removing 135 μl of 
the supernatant and replacing it with 135 μl serum-free medium. After washing the cells, cell 
viability was tested using MTT test [52,53]. Briefly, 45 μl of MTT solutions were added to each 
well (2 mg/ml, dissolved in serum-free medium). After 4 h of incubation, the plates were 
centrifuged at 2000 rpm for 5 min, and the supernatant was carefully removed. The precipitated 
purple crystals were dissolved in 100 μl DMSO, and after agitation for 10 min, the optical 
density (OD) of the solutions was determined at λ = 540 nm and 620 nm using an ELISA plate 
reader (iEMS Reader, Labsystems). Cell viability was calculated with the following equation 
(Eq. 1): 
 cell viability (%) = ୓ୈ౩
୓ୈౙ
× 100 (1) 
where ODୱ and ODୡ are the optical density of treated and control samples, respectively.  
The cytostatic activity of the samples was also determined. The cells were cultivated for 
additional 72 h after the washing steps with serum-free medium, as written above. Viability 
was determined by the MTT assay. All cytotoxicity and cytostatic measurements were repeated 
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twice on independently obtained cells (two sets of cultured cells); in each individual experiment 
the number of parallels was three. 
 
2.8. Drug release measurements  
The release of the FITC-dextran from PASP-FRFK hydrogels was studied in the presence 
of trypsin (Table 1). A piece of the gel was immersed into 20 ml of PBS containing 2 mg/ml 
trypsin. 2 ml samples were withdrawn and replaced with 2 ml fresh medium in every 60 min. 
The total amount of encapsulated drug was determined after the complete degradation of the 
gels.  
PASP-FRFK in PBS without trypsin and PASP-CA in PBS containing trypsin (Table 1 and 
Scheme S1) were used as reference samples. As these gels were expected to be stable during 
the drug release measurement, the total amount of encapsulated FITC-dextran was determined 
by dissolving these gels after the experiment. 40 mg trypsin was added to the release medium 
of the reference PASP-FRFK gels and 31 mg solid dithiothreitol was added to the release 
medium (to reach 10 mM concentration) of the PASP-CA gels to achieve their complete 
dissolution. The concentration of FITC-dextran in the samples was measured with a fluorimeter 
(PerkinElmer LS 50 B, USA, λex = 490 nm; λem = 515 nm). Experiments were carried out at 
37°C. Three parallel samples were measured in each experiment. 
 
3. Results and discussion 
3.1. Synthesis of enzyme-degradable hydrogel 
A trypsin-responsive poly(aspartic acid) hydrogel consisting exclusively of amino acids was 
successfully prepared by cross-linking polysuccinimide with a tetrapeptide followed by the 
alkaline hydrolysis of the resultant gel. Trypsin belongs to the chymotrypsin superfamily of 
serine endopeptidases. Human trypsin is formed in the small intestine from its precursor 
trypsinogen synthesized in the pancreas. The pH optimum of trypsin is 7.5-8.5. This enzyme 
hydrolyses the peptide bonds at the C-terminal side of lysine or arginine units. Secondary 
binding sites on both sides of the scissile bond play only a minor role, although occupancy of 
these sites does affect the catalytic efficiency of the trypsin [54].  
The FRFK tetrapeptide chosen as cross-linker in this study contains a trypsin-specific cleavage 
site between the second (arginine, R), and the third (phenylalanine, F) amino acid residues. 
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FRFK has free amino groups at both ends of the molecule, which can react with succinimide 
rings in a nucleophilic ring-opening reaction. In our case, these are the α-amino group of 
N-terminal phenylalanine (F) and the ε-amino group of C-terminal lysine (K). The cross-linking 
of polysuccinimide with the tetrapeptide was carried out in DMSO. As the synthesis of the 
tetrapeptide resulted in its TFA salt, DBA was used to obtain the free base. After gelation, the 
gel was immersed into imidazole buffer solution of pH = 8 to hydrolyse unreacted succinimide 
rings into aspartic acid residues. Finally, a stiff, transparent hydrogel formed. The synthesis 
route of the PASP-FRFK hydrogel is shown in Scheme 1. A representative image about the 
PASP-FRFK hydrogel is shown in Fig. 1. The gel strength was characterized by the storage 
modulus of the formed hydrogel. The frequency sweep test showed that the storage modulus of 
the hydrogel is much higher than the loss modulus in the entire frequency range probed (Fig. 
2) and its value was about 3 kPa with negligible frequency dependence indicating the formation 
of a chemically cross-linked hydrogel. 
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Scheme 1. Synthesis of PASP-FRFK hydrogel: PSI was cross-linked with FRFK tetrapeptide, after 
that the PSI-FRFK gel was hydrolysed to PASP-FRFK hydrogel in imidazole buffer (pH = 8); the 
scissors mark the cleavage site of the trypsin  
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Fig. 1. PASP-FRFK hydrogel loaded with FITC-dextran in PBS  
 
 
 
Fig. 2. Storage and loss modulus of the PASP-FRFK hydrogel as a function of angular 
frequency (γ = 1%, T = 25 °C).  
 
3.2. Enzymatic degradation of PASP-FRFK hydrogel  
The cross-linker, FRFK, contains a cleavage site specific to trypsin, thus we expected 
trypsin-induced enzymatic degradation of the PASP-FRFK hydrogel. A poly(aspartic acid) gel 
cross-linked with cystamine  (PASP-CA) was used in a control experiment as cystamine cannot 
be cleaved by trypsin (Scheme S1). The PASP-FRFK hydrogel completely dissolved in the 
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presence of trypsin within ca. 6 h, as shown by the complete weight loss (Fig. 3a) and 
disappearance of the gel (Fig. 3b). PASP-CA gel did not degrade under the same conditions 
(constant mass shown in Fig. 3a and Fig. S3). As these two gels differed only in the type of the 
cross-linker used, we can conclude that the degradation of the gel took place as a result of the 
enzymatic cleavage of the trypsin-specific cross-linker, and the polymer backbone remained 
intact. The enzymatic cleavage is further supported by the stability of PASP-FRFK hydrogel in 
the absence of trypsin (Fig. 3a). 
Surface and bulk erosion are the two main forms of degradation of a polymer hydrogel, 
however, surface and bulk erosion occur simultaneously for most materials. If surface erosion 
is prevalent, the polymer degrades from the exterior surface, resulting in size reduction over 
time, while the hydrogel maintains its bulk integrity. When bulk erosion is dominant, net points 
break evenly in the entire volume of the material, which leads to increasing degree of swelling 
in a significant part of the degradation, and the hydrogel splits into small fragments in the final 
stage of the process. In the first part of our experiment, the mass of PASP-FRFK hydrogel 
increased slightly (Fig. 3a) which implies bulk erosion, however, the edge of the sample became 
blurred (Fig. 3b) indicating that surface erosion occurs as well. After the second hour, the mass 
of the sample decreased at a constant rate (Fig. 3a), indicating that surface erosion became 
dominant. At the end of the experiment a homogeneous, transparent solution was obtained 
(Fig. 3b).  
The rate of the degradation of such hydrogel in an in vivo environment is influenced by the 
temperature and the concentration of the trypsin along the small intestine. The collected data is 
a good starting point for the proposed application, and the rate of the degradation can be tuned 
later by the degree of cross-linking and the sample size according to the transit time through 
the small intestine. 
  
13 
 
 
Fig. 3. (a) Changes in the relative mass of hydrogel samples as a function of time: PASP-
FRFK gel in trypsin, PASP- FRFK gel without trypsin and PASP-CA gel in trypsin solution. 
(b) Images of the degradation of PASP-FRFK hydrogel in PBS containing 2 mg/ml trypsin 
 
3.3. In vitro cytotoxicity and cytostatic activity  
In vitro cytotoxicity and cytostatic (anti-proliferative) activity testing have become 
important and critical aspects of characterizing the potential of new chemical entities. The in 
vitro cytotoxic and cytostatic effect of the digested PASP-FRFK, and its building blocks, the 
FRFK peptide and PASP were determined by a classic colorimetric end point MTT assay. The 
in vitro cytotoxicity and cytostatic activity of the compounds was measured using HepG2 
human hepatoma cell culture.  
Tetrazolium type compounds such as MTT, are widely used and accepted for in vitro 
assessment of metabolic activity of cells; this is one of the most frequently used methods for 
measuring cytotoxicity and cell proliferation [55]. IC50 represents the concentration of the 
a) 
b) 
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compound which is required for 50% inhibition. In the case of cytotoxicity, this value 
determines the concentration which destroys 50% of the cell population (direct killing), while 
in the case of cytostatic activity, it shows the concentration which inhibits the cell growth 
(proliferation) of 50% of the population. In our study, HepG2 cells have been used to determine 
in vitro hepatotoxicity because of their ability to sustain some liver-specific functions [56]. The 
data provide a starting point for further studies.  
The cells were treated with the FRFK peptide, PASP and the digested hydrogel solutions. 
The in vitro cytotoxicity and cytostatic activity of the compounds were characterized by the cell 
viability as shown in Figs. 4 and 5. Based on the data shown in Fig. 4, the building blocks of 
the hydrogel, PASP, and the FRFK peptide did not show cytotoxic (Fig 4a) or cytostatic effect 
(Fig. 4b). Viability was much above 50% in the covered concentration range on HepG2 cells.  
In order to estimate the biocompatibility of the digestion products of the PASP-FRFK 
hydrogel, digestion by trypsin was aborted at different times, after 4, 8, and 24 h. As the process 
advanced, the supernatant contained increasing amounts of the digestion products, and finally, 
no undigested hydrogel was left in the test tubes. The maximum concentration of digestion 
products on the cells was approximately 1.45 mg/ml after 24 h digestion which is comparable 
to that of the PASP and FRFK solutions in the assays. In this experiment, cell viability is 
compared to that of the trypsin solutions incubated for the same amount of time. According to 
the results shown on in Fig. 5, the digestion products of the hydrogel did not show cytotoxicity 
(Fig. 5a) and cytostatic activity (Fig. 5b) on HepG2 cell culture. Viability was much above 
50%. 
According to these data, the PASP-FRFK hydrogel is a promising material for biomedical 
applications as neither its building blocks nor its digestion products show harmful effects on 
HepG2 cells, although in further studies comprehensive analysis of the interactions between the 
hydrogel and different human cell lines (derived from blood system etc.) needs to be performed. 
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Fig. 4. (a) In vitro cytotoxicity of poly(aspartic acid) and the FRFK peptide and (b) in vitro 
cytostatic activity of poly(aspartic acid) and the FRFK peptide on HepG2 cell line 
 
 
Fig. 5. In vitro (a) cytotoxicity and (b) cytostatic activity of the supernatant of the digested 
PASP-FRFK hydrogel on HepG2 cell line 
 
3.4. Release of a macromolecular model drug  
In vitro drug release measurement was carried out since the PASP-FRFK hydrogel was 
designed for trypsin-induced controlled drug delivery. Fluorescein-isothiocyanate labelled 
dextran (Mw = 70000 Da) was used as model drug, which was encapsulated in the gels during 
the cross-linking process. 
a) b) 
a) b) 
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The PASP-FRFK gel released the model drug as a result of the enzymatic degradation of the 
gel matrix. After 6 h the gel dissolved completely and a homogenous solution containing the 
total amount of the encapsulated model drug was obtained. As shown in Fig. 6, the gel released 
it in a sustained manner. The drug release followed zero-order kinetic, the kinetic constant was 
calculated from the slope of the linear curve fitted to the first 6 h of the measurement and it was 
found to be k = 0.164 1/h. The reference samples, PASP-FRFK gel in the absence of trypsin 
and PASP-CA gel in the presence of trypsin remained stable during the 8 h of the experiment 
(Scheme S1) and a drug release of only 8% and 2%, respectively, was measured at the end of 
the experiment (the kinetic constants are summarized in Table 1).  These results prove that the 
FITC-dextran is entrapped in the PASP-FRFK gel and its release can be triggered by the 
presence of trypsin.  
 
 
Fig. 6. Release of the macromolecular drug as a function of time: PASP-FRFK gel in trypsin, 
PASP- FRFK gel without trypsin and PASP-CA gel in trypsin solution 
 
Table 1 Samples of the drug release measurement and the kinetic constants of drug release 
 
Gel Medium Degradation Kinetic constant (1/h) 
PASP-FRFK trypsin/PBS yes 1.64·10-1 
PASP-FRFK1 PBS no 9.49·10-3 
PASP-CA1 trypsin/PBS no 2.17·10-3 
 1 Reference samples 
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4. Conclusion 
A trypsin-degradable polymer gel consisting exclusively of amino acids was prepared in this 
study. A tetrapeptide was synthesized with a cleavage site specific to trypsin and was used to 
cross-link polysuccinimide. Poly(aspartic acid) hydrogel was obtained by alkaline hydrolysis. 
The synthesized hydrogel is degradable in the presence of trypsin and neither the polymer nor 
the cross-linker is cytotoxic and cytostatic according to in vitro tests on HepG2 cells. The 
encapsulated macromolecular drug is released from the gel in a sustained manner in the 
presence of trypsin, while the gel restrained the release of the drug in the absence of the enzyme. 
In light of the results, the gel can be made suitable for trypsin modulated release of drugs. The 
synthetic method can be extended to any peptide sequence with a free α-amine group at the N-
terminus and a lysine with free ε-amine group on the C-terminus, thus degradable hydrogels 
can be designed that are specific to any protease enzyme. 
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